Welcome to CreaSense
Accurate and affordable point-of-care testing for screening kidney disease
AboutUs
We are a research-driven team passionate about improving kidney health. Partnered with the Innovate UK ICURe Explore Programme, we at CreaSense are working on developing a simple, affordable and accurate sensing platform to detect Chronic Kidney Disease at early stages. The POCT device with a digital output would be a user-friendly device providing results in less than 5 mins with 80% accuracy. We aim to commercialize our research, collaborating with industry and academia to develop a point-care-care medical device that can be used in primary care clinics and for home-testing.
How It Works
We are developing an affordable and accurate point-of-care device for use in primary care clinics to screen CKD at early stages with 80% accuracy. The use of this device in clinics will allow accurate early diagnosis of CKD, preventing End-Stage Kidney Disease in diabetic and hypertensive patients. The low cost of the device will significantly add to cost savings in the healthcare system.
We are developing the test with
Speed
Accuracy
Affordable Test
The GlobalChallenge
Chronic Kidney Disease (CKD) presents a significant global health challenge, affecting more than 850 million individuals worldwide. In the United Kingdom, an estimated 7.2 million people have CKD, the scale of the issue becomes evident.
A SilentThreat
CKD is often referred to as a silent disease due to its asymptomatic nature, with symptoms often not manifesting until the disease has reached advanced stages. This silent progression not only impacts patients’ emotional and financial well-being but also places substantial burdens on healthcare systems and economies.
In India, where diabetes affects an estimated 11% of the population and is a significant contributor to CKD, and in the UK, where CKD results in direct costs of £6.4 billion to the NHS, the implications are clear. Additionally, individuals on dialysis due to kidney failure in the UK result in approximately £372 million in lost productivity, a figure projected to rise to £2 billion by 2033.
The ImperfectScreening
Current CKD screening methods, often relying on dipstick tests, have limitations in terms of accuracy, with rates ranging from 32% to 46%. These tests frequently miss early CKD cases, further exacerbating the problem. The colorimetric nature of these tests can also complicate result interpretation, impacting overall accuracy.
Share your Insights
We invite you to take part in our survey and contribute your insights to our ongoing research. By sharing your thoughts and experiences related to CKD screening and patient care, you can play an essential role in shaping the future of kidney health.
Accurate Early Detection
We are developing a point-of-care device that would ensure over 80% accuracy, facilitating the possibility of early CKD diagnosis for better patient outcomes
Efficiency and Speed
In under 5 minutes, our solution accelerates CKD screening, enabling informed decisions, shorter wait times, and optimised clinic workflows.
Cost Effective Care
Patient-Centric Approach
Our technology will be designed to integrate seamlessly into primary care clinic workflows, making the screening process more patient-centric.
OurSolution
At CreaSense, we are developing an accurate, simple and affordable medical device to diagnose early stages of CKD. We at CreaSense believe we can save lives of patients by diagnosing CKD at early stages in primary care clinics and in home-settings. This would reduce the economic burden of kidney disease in India where 210,000 cases of CKD are diagnosed each year. This could have a significant impact in areas where there is better need for access to primary care
Explore how our solution Works
The Different Clinical Settings
GP Surgeries
ICU & CCU
Cardiac Wards
